Carnobacterium is closely related to Lactobacillus and, similarly, is able to produce lactic acid which reduces intestinal pH and consequently inhibits the growth of many microorganisms and microbes, including pathogens. An important role in this process is also played by bacteriocins synthesized by Carnobacterium. These compounds resemble antibiotics in many respects. However, in contrast, they are completely safe for humans and animals and do not initiate the formation of resistant microorganisms. The bacteriocins do not disturb the natural balance of the intestinal ecosystem due to the highly specific activity. This is because most bacteriocins have a narrow range of activity and affect only several groups of microorganisms.
In 2012, a license agreement on paid use of the Carnobacterium divergens S1 strain was entered into with JHJ Sp. z o.o. In 2014, another license agreement was concluded, stipulating that JHJ Sp. z o.o. shall pay a license fee which consists of a flat license fee and a share in sales revenue.
The Carnobacterium divergens S1 strain was included in LAVIPAN®, a state-of-the-art probiotic preparation for poultry.
The use LAVIPAN® provides the following benefits:
- properly developed gastrointestinal microbiota,
- faster recovery after antibiotic treatments,
- reduction of diarrhea,
- significant improvement in weight gain, better feed utilization.
Currently, the offer of JHJ Sp. z o.o. includes several products based on the licensed strain.